

Self-Administered Autoimmune Injectables

Drugs, Devices, Packaging,
Therapeutics & Forecasts

Report Brochure


Greystone
Research Associates



Greystone Research Associates is pleased to announce the publication of a new market assessment. **Self-Administered Autoimmune Injectables: Drugs, Devices, Packaging, Therapeutics, Strategies and Forecasts** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for self-administered injectable drugs for treating autoimmune conditions. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Meaningful Therapeutic Outcomes and User-Friendly Presentations

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.



Executive Summary

Market Dynamics

Competitive Landscape
Drug Supply Chain Activity
Product Design and Enablement Factors
Ease of Use
Patient Adherence
Dosing Frequency
Human Engineering/Ergonomics
Pre- and Post-Marketing Device Evolution

Self-administered Injection – Enabling Devices

Device Selection - Stability and Material Issues
Prefilled Syringes
Autoinjectors
Special Feature Autoinjectors
Pen Injectors
Dual Chamber Pens
Emerging Devices

Autoimmune Drugs for Self-Administration – Full Product Profiles

mAbs
Cytokines
Fusion Proteins

Autoimmune Therapeutics Market Assessments

Ankylosing Spondylitis
Crohn's Disease
Adult Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
Multiple Sclerosis
Psoriatic Arthritis
Ulcerative Colitis

Market Factors

Regulatory Factors
Clinical Trial Protocols & Endpoints
Alliances and Partnerships

Company Profile

What You Will Learn

- What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?
- What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?
- What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2022?
- How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
- What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?
- What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-595-4340, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Fax to:
603-218-7020
or email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Research Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Self-Administered Autoimmune Injectables

Drugs, Devices, Packaging, Therapeutics and Forecasts

| Select | Format | License | Price (U.S. Funds) | Total |
|-----------------------------------|--------|---------------------|--------------------|-------|
| <input type="checkbox"/> | PDF | Single User License | \$3,850.00 | |
| <input type="checkbox"/> | PDF | Site License | \$5,500.00 | |
| <input type="checkbox"/> | PDF | Global License | \$7,500.00 | |
| Total Payment (U.S. funds) | | | | |

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

| Billing Information | Shipping Information |
|-----------------------|-----------------------------------------------------------------------------|
| Name: | <input type="checkbox"/> Click here if same as Billing Information Name: |
| Title: | Title: |
| Company: | Company: |
| Street Address: | Street Address: |
| City, State/Province: | City, State/Province: |
| Country/Postal Code: | Country/Postal Code: |
| Phone: | Phone: |
| Fax: | Fax: |
| Email: | Email: |